Researcher.Life Logo

HemaSphere : Impact Factor & More

eISSN: 2572-9241pISSN: 2572-9241
JournalOpen Access

Key Metrics

CiteScore
5.4
Impact Factor
5 - 10
Scite Index
0.90 5-Year SI
SJR
Q3Hematology
SNIP
0.9
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on HemaSphere

HemaSphere Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher LIPPINCOTT WILLIAMS & WILKINS
Language English
Frequency Monthly
Article Processing ChargesUSD 1200
Publication Time7
Editorial Review ProcessDouble anonymous peer review
General Details
LanguageEnglish
Society/Institute/SponsorEuropean Hematology Association
FrequencyMonthly
Publication Start Year2017
Publisher URLVisit website
Website URLVisit website
Publication Details
Other chargesVisit website
Publication Time 7
Editorial Review Detail
Editorial TeamVisit website
Review ProcessDouble anonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC, CC BY-SA, CC BY-NC-ND, CC BY-ND, CC BY-NC-SA
OA statementVisit website
View less

Planning to publish in HemaSphere ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in HemaSphere

CDK6 inactivation counteracts CALR\u2010mutant\u2010induced MPN evolution and sensitizes MPN stem cells to interferon\u2010\u03b1 treatment
  • 12 May 2026
  • HemaSphere
The rearrangement partner and the presence of MYC mutations determine the outcome of patients with MYC and BCL6 rearrangements
  • 12 May 2026
  • HemaSphere
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.
  • 1 May 2026
  • HemaSphere
Splenectomy in β-thalassemia patients: Practices and risks in a nationwide study.
  • 1 May 2026
  • HemaSphere
Factors associated with response to rituximab in patients with immune thrombocytopenia.
  • 1 May 2026
  • HemaSphere
Fitusiran treatment modulates the ratio between alpha- and beta-antithrombin isoforms.
  • 1 May 2026
  • HemaSphere
CDK6 inactivation counteracts CALR\u2010mutant\u2010induced MPN evolution and sensitizes MPN stem cells to interferon\u2010\u03b1 treatment
  • 12 May 2026
  • HemaSphere
The rearrangement partner and the presence of MYC mutations determine the outcome of patients with MYC and BCL6 rearrangements
  • 12 May 2026
  • HemaSphere
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.
  • 1 May 2026
  • HemaSphere
Splenectomy in β-thalassemia patients: Practices and risks in a nationwide study.
  • 1 May 2026
  • HemaSphere
Factors associated with response to rituximab in patients with immune thrombocytopenia.
  • 1 May 2026
  • HemaSphere
Fitusiran treatment modulates the ratio between alpha- and beta-antithrombin isoforms.
  • 1 May 2026
  • HemaSphere

FAQs on HemaSphere